Rare diseases: what's next?

被引：29

作者：

Remuzzi, Giuseppe ^{[1
]}

Garattini, Silvio ^{[1
]}

机构：

[1] Mario Negri Inst Pharmacol Res, Lab Negri Bergamo, Clin Res Ctr Rare Dis Aldo & Cele Dacco, I-24125 Bergamo, Italy

来源：

LANCET | 2008年 / 371卷 / 9629期

关键词：

D O I：

10.1016/S0140-6736(08)60847-8

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1978 / 1979

页数：2

共 11 条

[1] Empowerment of patients:: lessons from the rare diseases community [J].

Ayme, Segolene ;

Kole, Anna ;

Groft, Stephen .

LANCET, 2008, 371 (9629) :2048-2051

[2] Clinical trials of orphan medicines [J].

Buckley, Brendan M. .

LANCET, 2008, 371 (9629) :2051-2055

[3] Arsenic patent keeps drug for rare cancer out of reach of many [J].

Cyranoski, David .

NATURE MEDICINE, 2007, 13 (09) :1005-1005

[4]

*EUR COMM, 2007, PUBL CONS REG EUR AC

[5] Gene therapy of inherited diseases [J].

Fischer, Alain ;

Cavazzana-Calvo, Marina .

LANCET, 2008, 371 (9629) :2044-2047

[6]

*FRENCH NAT PLAN R, 2004, ENS EQ ACC DIAGN TRE

[7] Does orphan drug legislation really answer the needs of patients? [J].

Haffner, Marlene E. ;

Torrent-Farnell, Josep ;

Maher, Paul D. .

LANCET, 2008, 371 (9629) :2041-2044

[8] Orphan drug development is progressing too slowly [J].

Joppi, R ;

Bertele, V ;

Garattini, S .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 61 (03) :355-360

[9]

*OSS NAZ IMP FARM, 2006, US FARM IT

[10] Why rare diseases are an important medical and social issue [J].

Schieppati, Arrigo ;

Henter, Jan-Inge ;

Daina, Erica ;

Aperia, Anita .

LANCET, 2008, 371 (9629) :2039-2041

← 1 2 →